Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

52.76 +0.64 (+1.23%)
Official Closing Price Updated: 7:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,122,753
Open 52.03
Bid (Size) 52.71 (1)
Ask (Size) 53.26 (10)
Prev. Close 52.12
Today's Range 52.03 - 53.06
52wk Range 39.35 - 56.77
Shares Outstanding 2,222,113,553
Dividend Yield 4.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily

Performance

YTD
N/A
N/A
1 Month
+5.50%
+5.50%
3 Month
+22.75%
+22.75%
6 Month
+7.70%
+7.70%
1 Year
-5.79%
-5.79%

More News

Read More
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Via Benzinga
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Via The Motley Fool
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Via Investor's Business Daily
Exposures Product Safety
Unveiling 11 Analyst Insights On Bristol-Myers Squibb
Via Benzinga
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Via Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
Via Benzinga
Exposures COVID-19
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
2 Passive-Income Stocks to Load Up On in October
Via The Motley Fool
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
Via Investor's Business Daily
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
Via Benzinga
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Via The Motley Fool
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Via Benzinga
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
From Bristol Myers Squibb
Via Business Wire
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.